Verification of GLP-1 receptor agonist (Dulaglutide) additive effect on basal insulin therapy in patients with T2DM
Not Applicable
- Conditions
- Type2 diabetes
- Registration Number
- JPRN-UMIN000024447
- Lead Sponsor
- Japan Red Cross Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 48
Inclusion Criteria
Not provided
Exclusion Criteria
Type1 diabetes patients. Patients receiving insulin other than basal insulin. Patients who have used the GLP-1 receptor agonist in the past year. Patients who have a history of pancreatitis. During pregnancy , women who want to breast-feeding or during pregnancy . Patients attending physician has determined that there is a clinical problem in order to participate in the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Frequency of hypoglycemia
- Secondary Outcome Measures
Name Time Method The amount of change from baseline in HbA1c. The amount of change from baseline in bodyweight. The amount of change from the insulin dose of baseline. Frequency of adverse events.